Willem Mulder

List of Articles by Year
in descending order

Source: //exaly.com/author-pdf/1756343/publications.pdf

Version: 2025-02-01

183 peer-reviewed articles	15,732 peer-reviewed citations	13357 67 peer-reviewed h-index	87621 6.31 score
203 documents	20724 doc citations	12104 74 h-index	34868 citing authors

#	Article	IF	Citations
1	Engineering Fusion Proteins for Nanomedicine-Based Cytokine Therapy. Bioconjugate Chemistry, 2025, 36, 1698-1708.	2.9	1
2	Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy. Nature Nanotechnology, 2024, 19, 1735-1744.	23.4	35
3	Trained immunity suppression determines kidney allograft survival. American Journal of Transplantation, 2024, 24, 2022-2033.	3.4	13
4	Trained immunity: adaptation within innate immune mechanisms. Physiological Reviews, 2023, 103, 313-346.	20.1	199
5	CHECKPOINT ATHERO: developing immune checkpoint-based therapeutics for atherosclerosis. European Heart Journal, 2023, 44, 1010-1012.	2.6	10
6	Engineering cytokine therapeutics. Nature Reviews Bioengineering, 2023, 1, 286-303.	24.2	202
7	Resolving sepsis-induced immunoparalysis via trained immunity by targeting interleukin-4 to myeloid cells. Nature Biomedical Engineering, 2023, 7, 1097-1112.	14.4	88
8	Trained immunity in atherosclerotic cardiovascular disease. Nature Reviews Cardiology, 2023, 20, 799-811.	25.1	112
9	Cardiovascular Molecular Imaging With Fluorine-19 MRI: The Road to the Clinic. Circulation: Cardiovascular Imaging, 2023, 16, .	2.4	11
10	Trained immunity: Target for prophylaxis and therapy. Cell Host and Microbe, 2023, 31, 1776-1791.	12.2	85
11	Regulating trained immunity with nanomedicine. Nature Reviews Materials, 2022, 7, 465-481.	56.8	108
12	Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation. Scientific Reports, 2022, 12, .	2.7	45
13	Trained immunity — basic concepts and contributions to immunopathology. Nature Reviews Nephrology, 2022, 19, 23-37.	24.2	442
14	Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma. Nature Communications, 2022, 13, .	10.8	21
15	A modular approach toward producing nanotherapeutics targeting the innate immune system. Science Advances, 2021, 7, .	8.1	43
16	Prosaposin mediates inflammation in atherosclerosis. Science Translational Medicine, 2021, 13, .	8.7	98
17	Embracing nanomaterials' interactions with the innate immune system. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, .	5.2	21
18	Cyclic Arginine–Glycine–Aspartate-Decorated Lipid Nanoparticle Targeting toward Inflammatory Lesions Involves Hitchhiking with Phagocytes. Advanced Science, 2021, 8, .	7.7	11

#	Article	IF	Citations
19	Employing nanobodies for immune landscape profiling by PET imaging in mice. STAR Protocols, 2021, 2, 100434.	0.8	12
20	Targeting Trained Innate Immunity With Nanobiologics to Treat Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1839-1850.	4.3	17
21	Nanoengineering Apolipoprotein A1-Based Immunotherapeutics. Advanced Therapeutics, 2021, 4, .	1.6	19
22	Imaging-guided nanomedicine development. Current Opinion in Chemical Biology, 2021, 63, 78-85.	4.6	23
23	Kinase Inhibitors' Effects on Innate Immunity in Solid Cancers. Cancers, 2021, 13, 5695.	2.7	6
24	Diverse ultrastructural landscape of atherosclerotic endothelium. Atherosclerosis, 2021, 339, 35-45.	1.9	13
25	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of 89Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. Bioconjugate Chemistry, 2020, 31, 360-368.	2.9	30
26	Trained immunity in organ transplantation. American Journal of Transplantation, 2020, 20, 10-18.	3.4	112
27	An 89Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor. Journal of Nuclear Medicine, 2020, 61, 433-436.	4.0	33
28	An iterative sparse deconvolution method for simultaneous multicolor 19F-MRI of multiple contrast agents. Magnetic Resonance in Medicine, 2020, 83, 228-239.	2.4	30
29	Imaging Cardiovascular and Lung Macrophages With the Positron Emission Tomography Sensor ^{64}Cu-Macrin in Mice, Rabbits, and Pigs. Circulation: Cardiovascular Imaging, 2020, 13, .	2.4	46
30	Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis. JACC: CardioOncology, 2020, 2, 599-610.	3.8	141
31	Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell Reports Medicine, 2020, 1, 100146.	5.3	36
32	Nuclear imaging approaches facilitating nanomedicine translation. Advanced Drug Delivery Reviews, 2020, 154-155, 123-141.	12.5	77
33	Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition. Cell, 2020, 183, 786-801.e19.	23.4	211
34	Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice. Cells, 2020, 9, 1987.	3.3	80
35	Multimodal imaging of bacterial-host interface in mice and piglets with Staphylococcus aureus endocarditis. Science Translational Medicine, 2020, 12, .	8.7	12
36	Whole-Body Atherosclerosis Imaging by Positron Emission Tomography/Magnetic Resonance Imaging. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1123-1134.	4.3	9

#	Article	IF	Citations
37	Tumor Targeting by αvβ3-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking. ACS Nano, 2020, 14, 7832-7846.	11.5	112
38	Defining trained immunity and its role in health and disease. Nature Reviews Immunology, 2020, 20, 375-388.	32.3	2,545
39	Atherosclerosis Immunoimaging by Positron Emission Tomography. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 865-873.	4.3	33
40	Probing myeloid cell dynamics in ischaemic heart disease by nanotracer hot-spot imaging. Nature Nanotechnology, 2020, 15, 398-405.	23.4	61
41	Ultra-high resolution, 3-dimensional magnetic resonance imaging of the atherosclerotic vessel wall at clinical 7T. PLoS ONE, 2020, 15, e0241779.	1.5	5
42	Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. Science Translational Medicine, 2019, 11, .	8.7	69
43	Nanoparticle-Aided Characterization of Arterial Endothelial Architecture during Atherosclerosis Progression and Metabolic Therapy. ACS Nano, 2019, 13, 13759-13774.	11.5	107
44	Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC: Cardiovascular Imaging, 2019, 12, 2015-2026.	3.9	94
45	Hybrid PET- and MR-driven attenuation correction for enhanced 18F-NaF and 18F-FDG quantification in cardiovascular PET/MR imaging. Journal of Nuclear Cardiology, 2019, 27, 1126-1141.	0.8	24
46	Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nature Biomedical Engineering, 2018, 2, 279-292.	14.4	128
47	Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. Journal of the American College of Cardiology, 2018, 71, 527-542.	0.7	198
48	PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis. Journal of the American College of Cardiology, 2018, 71, 321-335.	0.7	54
49	RAF/MEK/extracellular signal–related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. Journal of Experimental Medicine, 2018, 215, 319-336.	5.9	75
50	High-Density Lipoprotein Nanobiologics for Precision Medicine. Accounts of Chemical Research, 2018, 51, 127-137.	11.6	83
51	Neutrophil derived CSF1 induces macrophage polarization and promotes transplantation tolerance. American Journal of Transplantation, 2018, 18, 1247-1255.	3.4	94
52	Reversible Electroporation–Mediated Liposomal Doxorubicin Delivery to Tumors Can Be Monitored With ^{89}Zr-Labeled Reporter Nanoparticles. Molecular Imaging, 2018, 17, .	1.4	26
53	Current and Emerging Preclinical Approaches for Imaging-Based Characterization of Atherosclerosis. Molecular Imaging and Biology, 2018, 20, 869-887.	1.6	22
54	Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer. Bioconjugate Chemistry, 2018, 29, 3776-3782.	2.9	20

#	Article	IF	Citations
55	Monocyte and Macrophage Dynamics in the Cardiovascular System. Journal of the American College of Cardiology, 2018, 72, 2198-2212.	0.7	55
56	Targeting myeloperoxidase in inflammatory atherosclerosis. European Heart Journal, 2018, 39, 3311-3313.	2.6	26
57	Sonophore-enhanced nanoemulsions for optoacoustic imaging of cancer. Chemical Science, 2018, 9, 5646-5657.	5.3	30
58	Investigating supramolecular systems using Förster resonance energy transfer. Chemical Society Reviews, 2018, 47, 7027-7044.	32.1	166
59	Nanoimmunotherapy to treat ischaemic heart disease. Nature Reviews Cardiology, 2018, 16, 21-32.	25.1	59
60	Real-Time Monitoring of Nanoparticle Formation by FRET Imaging. Angewandte Chemie, 2017, 129, 2969-2972.	0.9	8
61	Real-Time Monitoring of Nanoparticle Formation by FRET Imaging. Angewandte Chemie - International Edition, 2017, 56, 2923-2926.	11.6	35
62	Polyglucose nanoparticles with renal elimination and macrophage avidity facilitate PET imaging in ischaemic heart disease. Nature Communications, 2017, 8, .	10.8	149
63	Applying nanomedicine in maladaptive inflammation and angiogenesis. Advanced Drug Delivery Reviews, 2017, 119, 143-158.	12.5	62
64	Hyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in Atherosclerosis. ACS Nano, 2017, 11, 5785-5799.	11.5	189
65	Investigating the Cellular Specificity in Tumors of a Surface-Converting Nanoparticle by Multimodal Imaging. Bioconjugate Chemistry, 2017, 28, 1413-1421.	2.9	17
66	Near-Infrared Quantum Dot and 89Zr Dual-Labeled Nanoparticles for in Vivo Cerenkov Imaging. Bioconjugate Chemistry, 2017, 28, 600-608.	2.9	39
67	Cardiovascular Immunotherapy and the Role of Imaging. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, .	4.3	6
68	Integrating nanomedicine and imaging. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2017, 375, 20170110.	1.6	6
69	Specific Binding of Liposomal Nanoparticles through Inverse Electron-Demand Diels–Alder Click Chemistry. ChemistryOpen, 2017, 6, 615-619.	1.9	9
70	A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. Journal of Controlled Release, 2017, 262, 47-57.	8.1	54
71	A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines. Journal of Visualized Experiments, 2017, , .	0.2	6
72	A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines. Journal of Visualized Experiments, 2017, , .	0.2	0

#	Article	IF	Citations
73	Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. Nature Communications, 2016, 7, .	10.8	113
74	Conformational Changes in High-Density Lipoprotein Nanoparticles Induced by High Payloads of Paramagnetic Lipids. ACS Omega, 2016, 1, 470-475.	3.4	4
75	Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1463-1470.	2.3	38
76	Immune cell screening of a nanoparticle library improves atherosclerosis therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, .	5.2	112
77	Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy. Nature Communications, 2016, 7, .	10.8	131
78	HDL mimetic CER-001 targets atherosclerotic plaques in patients. Atherosclerosis, 2016, 251, 381-388.	1.9	59
79	In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. JACC: Cardiovascular Imaging, 2016, 9, 950-961.	3.9	96
80	Systems Biology and Noninvasive Imaging of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, .	4.3	12
81	Combination nanotherapy penetrates atherosclerosis. Cardiovascular Research, 2016, 109, 191-192.	5.7	1
82	Three-dimensional dynamic contrast-enhanced MRI for the accurate, extensive quantification of microvascular permeability in atherosclerotic plaques. NMR in Biomedicine, 2015, 28, 1304-1314.	1.9	33
83	Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1133-1140.	2.3	44
84	Nanomedicines for endothelial disorders. Nano Today, 2015, 10, 759-776.	7.3	55
85	HDL-Mimetic PLGA Nanoparticle To Target Atherosclerosis Plaque Macrophages. Bioconjugate Chemistry, 2015, 26, 443-451.	2.9	162
86	Atherosclerotic Plaque Targeting Mechanism of Long-Circulating Nanoparticles Established by Multimodal Imaging. ACS Nano, 2015, 9, 1837-1847.	11.5	120
87	PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles. Journal of Nuclear Medicine, 2015, 56, 1272-1277.	4.0	164
88	Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1039-1046.	2.3	166
89	Imaging Systemic Inflammatory Networks in Ischemic Heart Disease. Journal of the American College of Cardiology, 2015, 65, 1583-1591.	0.7	77
90	Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Science Advances, 2015, 1, .	8.1	220

#	Article	IF	Citations
91	Imaging Macrophage and Hematopoietic Progenitor Proliferation in Atherosclerosis. Circulation Research, 2015, 117, 835-845.	8.6	83
92	Probing Lipid Coating Dynamics of Quantum Dot Core Micelles via Förster Resonance Energy Transfer. Small, 2014, 10, 1163-1170.	7.3	12
93	Imaging and Nanomedicine in Inflammatory Atherosclerosis. Science Translational Medicine, 2014, 6, .	8.7	179
94	Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1078-1083.	5.2	186
95	A Modular Labeling Strategy for In Vivo PET and Near-Infrared Fluorescence Imaging of Nanoparticle Tumor Targeting. Journal of Nuclear Medicine, 2014, 55, 1706-1711.	4.0	95
96	In Vivo Imaging of Enhanced Leukocyte Accumulation in Atherosclerotic Lesions in Humans. Journal of the American College of Cardiology, 2014, 64, 1019-1029.	0.7	44
97	Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation in Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2014, 64, 1418-1426.	0.7	106
98	A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nature Communications, 2014, 5, .	10.8	398
99	Synthesis and in vitro evaluation of a multifunctional and surface-switchable nanoemulsion platform. Chemical Communications, 2013, 49, 9392.	2.4	16
100	The Complex Fate in Plasma of Gadolinium Incorporated into High-Density Lipoproteins Used for Magnetic Imaging of Atherosclerotic Plaques. Bioconjugate Chemistry, 2013, 24, 1039-1048.	2.9	12
101	Synthesis of Polymer–Lipid Nanoparticles for Image-Guided Delivery of Dual Modality Therapy. Bioconjugate Chemistry, 2013, 24, 1429-1434.	2.9	111
102	MRI of ICAM-1 Upregulation After Stroke: the Importance of Choosing the Appropriate Target-Specific Particulate Contrast Agent. Molecular Imaging and Biology, 2013, 15, 411-422.	1.6	53
103	Single Step Reconstitution of Multifunctional High-Density Lipoprotein-Derived Nanomaterials Using Microfluidics. ACS Nano, 2013, 7, 9975-9983.	11.5	118
104	Gold Nanocrystal Labeling Allows Low-Density Lipoprotein Imaging from the Subcellular to Macroscopic Level. ACS Nano, 2013, 7, 9761-9770.	11.5	81
105	Near-Infrared Fluorescence Energy Transfer Imaging of Nanoparticle Accumulation and Dissociation Kinetics in Tumor-Bearing Mice. ACS Nano, 2013, 7, 10362-10370.	11.5	66
106	Multifunctional Gold Nanoparticles for Diagnosis and Therapy of Disease. Molecular Pharmaceutics, 2013, 10, 831-847.	3.2	681
107	Collagen-Specific Peptide Conjugated HDL Nanoparticles as MRI Contrast Agent to Evaluate Compositional Changes in Atherosclerotic Plaque Regression. JACC: Cardiovascular Imaging, 2013, 6, 373-384.	3.9	78
108	Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Review of Molecular Diagnostics, 2013, 13, 567-580.	2.3	93

#	Article	IF	Citations
109	Inorganic nanocrystals as contrast agents in MRI: synthesis, coating and introduction of multifunctionality. NMR in Biomedicine, 2013, 26, 766-780.	1.9	49
110	High-density lipoprotein is a nanoparticle, but not all nanoparticles are high-density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, .	5.2	6
111	Periodicity in tumor vasculature targeting kinetics of ligand-functionalized nanoparticles studied by dynamic contrast enhanced magnetic resonance imaging and intravital microscopy. Angiogenesis, 2013, 17, 93-107.	5.8	14
112	Nanoclusters of Iron Oxide: Effect of Core Composition on Structure, Biocompatibility, and Cell Labeling Efficacy. Bioconjugate Chemistry, 2012, 23, 941-950.	2.9	14
113	Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging. Chemical Communications, 2012, 48, 5835.	2.4	91
114	Tumor Angiogenesis Phenotyping by Nanoparticle-facilitated Magnetic Resonance and Near-infrared Fluorescence Molecular Imaging. Neoplasia, 2012, 14, 964-973.	2.7	29
115	Mass Production and Size Control of Lipid–Polymer Hybrid Nanoparticles through Controlled Microvortices. Nano Letters, 2012, 12, 3587-3591.	6.2	223
116	Molecular MR Imaging of Collagen in Mouse Atherosclerosis by Using Paramagnetic CNA35 Micelles. European Journal of Inorganic Chemistry, 2012, 2012, 2115-2125.	1.2	22
117	The Effect of Nanoparticle Polyethylene Glycol Surface Density on Ligand-Directed Tumor Targeting Studiedin Vivoby Dual Modality Imaging. ACS Nano, 2012, 6, 5648-5658.	11.5	196
118	Nanocrystal Core Lipoprotein Biomimetics for Imaging of Lipoproteins and Associated Diseases. Current Cardiovascular Imaging Reports, 2012, 6, 45-54.	0.3	6
119	A Versatile and Tunable Coating Strategy Allows Control of Nanocrystal Delivery to Cell Types in the Liver. Bioconjugate Chemistry, 2011, 22, 353-361.	2.9	41
120	In Vivo Characterization of a New Abdominal Aortic Aneurysm Mouse Model With Conventional and Molecular Magnetic Resonance Imaging. Journal of the American College of Cardiology, 2011, 58, 2522-2530.	0.7	80
121	Multifunctional Nanoemulsion Platform for Imaging Guided Therapy Evaluated in Experimental Cancer. ACS Nano, 2011, 5, 4422-4433.	11.5	192
122	Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nature Reviews Drug Discovery, 2011, 10, 835-852.	43.4	390
123	Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2011, 3, 146-161.	5.2	58
124	Contrast enhancement by differently sized paramagnetic MRI contrast agents in mice with two phenotypes of atherosclerotic plaque. Contrast Media and Molecular Imaging, 2011, 6, 35-45.	0.0	30
125	Influence of cell-internalization on relaxometric, optical and compositional properties of targeted paramagnetic quantum dot micelles. Contrast Media and Molecular Imaging, 2011, 6, 100-109.	0.0	10
126	The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials, 2011, 32, 206-213.	9.5	65

#	Article	IF	Citations
127	Science to Practice: Versatile Method to Track Transplanted Encapsulated Islet Cells with Multiple Imaging Modalities. Radiology, 2011, 258, 1-2.	6.7	9
128	Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. Nature Reviews Cardiology, 2011, 8, 338-347.	25.1	72
129	Nanomedical Theranostics in Cardiovascular Disease. Current Cardiovascular Imaging Reports, 2011, 5, 19-25.	0.3	57
130	Modified natural nanoparticles as contrast agents for medical imaging. Advanced Drug Delivery Reviews, 2010, 62, 329-338.	12.5	185
131	Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis, 2010, 13, 161-173.	5.8	101
132	Quantum dots for multimodal molecular imaging of angiogenesis. Angiogenesis, 2010, 13, 131-134.	5.8	38
133	A fluorescent, paramagnetic and PEGylated gold/silica nanoparticle for MRI, CT and fluorescence imaging. Contrast Media and Molecular Imaging, 2010, 5, 231-236.	0.0	113
134	Multifunctional imaging nanoprobes. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2010, 2, 138-150.	5.2	73
135	Imaging and quantifying the morphology of an organic–inorganic nanoparticle at the sub-nanometre level. Nature Nanotechnology, 2010, 5, 538-544.	23.4	68
136	Magnetic Resonance Molecular Imaging of Thrombosis in an Arachidonic Acid Mouse Model Using an Activated Platelet Targeted Probe. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 403-410.	4.3	50
137	RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB Journal, 2010, 24, 1689-1699.	2.3	109
138	Atherosclerotic Plaque Composition: Analysis with Multicolor CT and Targeted Gold Nanoparticles. Radiology, 2010, 256, 774-782.	6.7	473
139	High-Density Lipoprotein–Based Contrast Agents for Multimodal Imaging of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 169-176.	4.3	110
140	Multimodal Clinical Imaging To Longitudinally Assess a Nanomedical Anti-Inflammatory Treatment in Experimental Atherosclerosis. Molecular Pharmaceutics, 2010, 7, 2020-2029.	3.2	162
141	Annexin A5-Functionalized Bimodal Nanoparticles for MRI and Fluorescence Imaging of Atherosclerotic Plaques. Bioconjugate Chemistry, 2010, 21, 1794-1803.	2.9	101
142	Quantum Dot and Cy5.5 Labeled Nanoparticles to Investigate Lipoprotein Biointeractions via Förster Resonance Energy Transfer. Nano Letters, 2010, 10, 5131-5138.	6.2	76
143	Synergistic Targeting of αvβ3 Integrin and Galectin-1 with Heteromultivalent Paramagnetic Liposomes for Combined MR Imaging and Treatment of Angiogenesis. Nano Letters, 2010, 10, 52-58.	6.2	147
144	Nanotechnology in Medical Imaging. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 992-1000.	4.3	277

#	Article	IF	Citations
145	Morphology, binding behavior and MR-properties of paramagnetic collagen-binding liposomes. Contrast Media and Molecular Imaging, 2009, 4, 81-88.	0.0	43
146	CMR2009: 10.07: Multimodality investigation of lipoprotein metabolism in a mouse model of atherosclerosis using iron oxide core high-density lipoprotein nano-particles. Contrast Media and Molecular Imaging, 2009, 4, 293-294.	0.0	0
147	Cellular compartmentalization of internalized paramagnetic liposomes strongly influences both T1 and T2 relaxivity. Magnetic Resonance in Medicine, 2009, 61, 1022-1032.	2.4	73
148	Tyrosine polyethylene glycol (PEG)-micelle magnetic resonance contrast agent for the detection of lipid rich areas in atherosclerotic plaque. Magnetic Resonance in Medicine, 2009, 62, 1195-1201.	2.4	34
149	Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging. Biomaterials, 2009, 30, 6947-6954.	9.5	105
150	Magnetic quantum dots for multimodal imaging. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2009, 1, 475-491.	5.2	83
151	High-Relaxivity Gadolinium-Modified High-Density Lipoproteins as Magnetic Resonance Imaging Contrast Agents. Journal of Physical Chemistry B, 2009, 113, 6283-6289.	2.0	65
152	Comparison of Synthetic High Density Lipoprotein (HDL) Contrast Agents for MR Imaging of Atherosclerosis. Bioconjugate Chemistry, 2009, 20, 937-943.	2.9	67
153	Well-Defined, Multifunctional Nanostructures of a Paramagnetic Lipid and a Lipopeptide for Macrophage Imaging. Journal of the American Chemical Society, 2009, 131, 406-407.	11.7	30
154	Nanoparticulate Assemblies of Amphiphiles and Diagnostically Active Materials for Multimodality Imaging. Accounts of Chemical Research, 2009, 42, 904-914.	11.6	261
155	An ApoA-I Mimetic Peptide High-Density-Lipoprotein-Based MRI Contrast Agent for Atherosclerotic Plaque Composition Detection. Small, 2008, 4, 1437-1444.	7.3	105
156	Kinetics of avidin-induced clearance of biotinylated bimodal liposomes for improved MR molecular imaging. Magnetic Resonance in Medicine, 2008, 60, 1444-1456.	2.4	29
157	Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media and Molecular Imaging, 2008, 3, 233-242.	0.0	87
158	Paramagnetic Lipid-Coated Silica Nanoparticles with a Fluorescent Quantum Dot Core: A New Contrast Agent Platform for Multimodality Imaging. Bioconjugate Chemistry, 2008, 19, 2471-2479.	2.9	149
159	Nanocrystal Core High-Density Lipoproteins: A Multimodality Contrast Agent Platform. Nano Letters, 2008, 8, 3715-3723.	6.2	323
160	Improved Magnetic Resonance Molecular Imaging of Tumor Angiogenesis by Avidin-Induced Clearance of Nonbound Bimodal Liposomes. Neoplasia, 2008, 10, 1459-1469.	2.7	33
161	Improved Biocompatibility and Pharmacokinetics of Silica Nanoparticles by Means of a Lipid Coating: A Multimodality Investigation. Nano Letters, 2008, 8, 2517-2525.	6.2	240
162	Multimodality nanotracers for cardiovascular applications. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, S103-S111.	0.0	49

#	Article	IF	Citations
163	Targeted Molecular Probes for Imaging Atherosclerotic Lesions With Magnetic Resonance Using Antibodies That Recognize Oxidation-Specific Epitopes. Circulation, 2008, 117, 3206-3215.	13.1	181
164	Molecular imaging of tumor angiogenesis using αvβ3-integrin targeted multimodal quantum dots. Angiogenesis, 2008, 12, 17-24.	5.8	145
165	Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB Journal, 2007, 21, 378-383.	2.3	82
166	Magnetic Resonance Molecular Imaging Contrast Agents and Their Application in Atherosclerosis. Topics in Magnetic Resonance Imaging, 2007, 18, 409-417.	0.3	26
167	Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine, 2007, 2, 307-324.	2.5	170
168	Anginex-Conjugated Liposomes for Targeting of Angiogenic Endothelial Cells. Bioconjugate Chemistry, 2007, 18, 785-790.	2.9	41
169	Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magnetic Resonance in Medicine, 2007, 58, 1164-1170.	2.4	131
170	Magnetic resonance imaging of vulnerable atherosclerotic plaques: Current imaging strategies and molecular imaging probes. Journal of Magnetic Resonance Imaging, 2007, 26, 460-479.	2.6	132
171	Quantum Dots with a Paramagnetic Coating as a Bimodal Molecular Imaging Probe. Nano Letters, 2006, 6, 1-6.	6.2	492
172	Annexin A5-Functionalized Bimodal Lipid-Based Contrast Agents for the Detection of Apoptosis. Bioconjugate Chemistry, 2006, 17, 741-749.	2.9	118
173	Annexin A5-Conjugated Quantum Dots with a Paramagnetic Lipidic Coating for the Multimodal Detection of Apoptotic Cells. Bioconjugate Chemistry, 2006, 17, 865-868.	2.9	142
174	Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR in Biomedicine, 2006, 19, 142-164.	1.9	529
175	Relaxivity of liposomal paramagnetic MRI contrast agents. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2005, 18, 186-192.	1.4	134
176	MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB Journal, 2005, 19, 2008-2010.	2.3	250
177	A Liposomal System for Contrast-Enhanced Magnetic Resonance Imaging of Molecular Targets. Bioconjugate Chemistry, 2004, 15, 799-806.	2.9	218
178	Preparation and stability of lipid-coated nanocapsules of cisplatin: anionic phospholipid specificity. Biochimica Et Biophysica Acta - Biomembranes, 2004, 1663, 135-142.	1.5	31
179	Preparation and stability of lipid-coated nanocapsules of cisplatin: anionic phospholipid specificity. Biochimica Et Biophysica Acta - Biomembranes, 2004, 1663, 135-142.	1.5	0
180	Radiolabeling lipoproteins to study and manage disease. European Journal of Nuclear Medicine and Molecular Imaging, 0, 52, 4717-4734.	4.0	2

#	Article	IF	Citations
181	Immunotherapy for atherosclerosis. Physiological Reviews, 0, , .	20.1	20
182	Systemically inducing trained immunity overcomes solid tumors' immunosuppressive microenvironment. Science Advances, 0, 12, .	8.1	12
183	Immuno-imaging in solid organ transplantation. American Journal of Transplantation, 0, 26, 1551-1560.	3.4	0